Eli Lilly unveiled plans for a $3.5 billion manufacturing facility in Lehigh Valley, Pennsylvania, dedicated to producing retatrutide and other obesity injectables and devices. The investment is intended to secure supply for Lilly’s next‑generation weight‑loss portfolio as global demand grows. The plant represents a vertical expansion into device-enabled biologics manufacturing and signals pharma’s broader strategy to lock in capacity for high‑margin metabolic drugs amid intense competition for production slots.